INTRODUCTION
Spinal muscular atrophy (SMA) is a motor neuron disease characterized by degeneration of spinal cord anterior horn cells and muscular atrophy. The autosomal recessive form of this disorder affects about 1:10 000 live births with a carrier frequency of 1/40-1/60. It is the most common fatal genetic disorder of infancy and the second most common childhood neuromuscular disease following Duchenne muscular dystrophy. Childhoodonset SMA is classified into three clinical subtypes: (i) SMA type I, or Werdnig-Hoffmann disease-the most severe phenotype, usually leading to early infant death; (ii) SMA type II, or the intermediate subtype-onset in early childhood often resulting in early impairment of walking; and (iii) SMA type III, or Kugelberg-Welander disease-onset in late childhood, with considerable clinical heterogeneity and the risk of wheelchair dependence in adult years. The gene for the three types of childhood-onset SMA has been mapped to a single locus on chromosome 5q13 by linkage analysis (1) (2) (3) . Further studies using recombinant mapping methods identified a genetic interval of 1-2 cM flanked by new microsatellite markers (4) (5) (6) (7) 13) . Several YAC contigs spanning the SMA gene region have been constructed by different research groups (5, 8, 9, 11 ). Further refinement of the region was complicated by low-copy repeat sequences mapping in and around the SMA region (8, (11) (12) (13) . Gene-coding sequences likewise tend to exist in multiple copies within the disease gene region. In some cases pseudogenes map to the SMA region while the intact, presumably functional, copies map elsewhere in the genome (14) .
Recently, independent laboratories reported two candidate genes in the SMA region: the survival motor neuron (SMN) gene and the neuronal apoptosis inhibitory protein (NAIP) (15, 16) . The survival motor neuron (SMN) gene exists as two highly homologous copies, a centromeric (SMN C ) and a telomeric form (SMN T ) which differ by only 2 bp in the entire 1.5 kb coding sequence. The SMN T copy is homozygously missing in over 90% of SMA patients, whereas at least one copy of SMN T is present in the vast majority of control DNA samples (15, (17) (18) (19) . SMN C is not preferentially deleted in SMA patients, but is homozygously deleted in about 5% of samples tested. Expression of the SMN C *To whom correspondence should be addressed at: 722 West 168th Street, Unit 23, New York, NY 10032, USA gene appears to differ in SMA versus control samples. In samples lacking a copy of SMN T , there is a noticeable increase in the expression of an alternatively spliced SMN C RNA transcript (15) . Thus, while SMN C does not appear to be a target for SMA mutations, its pattern of expression may contribute to the pathophysiology of the disorder.
The second candidate gene, NAIP, maps in the near vicinity of SMN T . NAIP likewise exists in multiple, highly homologous copies, although it appears that only one copy contains the full complement of exons. The intact copy of NAIP is homozygously deleted in about 40% of SMA type I cases and to a lesser extent in SMA II and III individuals (16, 19) . In the minority of SMA samples where no evidence was found for deletion of either SMN T or NAIP, several small insertion/deletion mutations have been found at the splice-site junctions of SMN T (15) .
In summary, three types of evidence implicate SMN as the most critical gene influencing the onset of SMA: first, deletion of the 3′-end of SMN T is most highly correlated with incidence of SMA; second, a minority of SMA patients reveal small insertion/ deletion mutations at splice-site junctions in SMN T whereas no disease-related point mutations have been reported for NAIP; and third, homozygous deletion of intact NAIP has been reported in asymptomatic parents of SMA patients (16) , while recent evidence shows that SMN T is likewise missing in a small fraction of asymptomatic SMA siblings and parents (18, 19 ; this manuscript).
From the sum of evidence available to date, it is still not clear whether all cases of SMA arise from deletions or alteration of the SMN T gene. Five to 10% of SMA samples reveal at least one SMN T gene with intact exons 7 and 8. As current single strand conformation polymorphism (SSCP) assays cannot distinguish the 5′-ends of the SMN T and SMN C genes, it is very difficult to screen for deletions specific for this region of the gene. Furthermore, the promoter sequences for SMN T have not yet been identified, nor has the full intronic DNA sequence been reported. Thus, it is not known whether the remaining 5-10% of SMA cases actually harbor deletions including the 5′-end of SMN T , or deletions or point mutations in the promoter or intronic sequences. If they do not, then a small proportion of SMA cases presumably arise from the inactivation of other genes, including but not necessarily limited to NAIP.
To evaluate further the part of SMN T in the etiology of SMA, we performed clinical assessment of individuals who are homozygous null for SMN T exons 7 and 8. The identification of such asymptomatic individuals might indicate that deletion of SMN T (exons 7 and 8) alone is insufficient to cause SMA symptoms, or alternatively, that compensating factors can, in rare cases, override the deletion and lead to a 'normal' phenotype. We screened 280 asymptomatic family members (214 parents and 66 siblings) of SMA patients for homozygous deletion of SMN exons 7 and 8. Two asymptomatic parents from different families were identified who are missing both exons 7 and 8. One parent showed neurogenic abnormalities in electromyography (EMG) and muscle biopsy, consistent with subclinical SMA. The other parent, who has a normal EMG and muscle biopsy, was from a family that appeared to be unlinked to the chromosome 5q13 DNA markers (2, 20) . We now show that this family is actually consistent with chromosome 5q13 linkage and that the parent transmits different mutant chromosomes to two affected offsprings. Table. n = the number of asymptomatic family members analyzed. The numbers in the three columns indicate the number of individuals missing both copies of exon 7, exon 8 or exons 7 and 8. Twelve aysmptomatic family members (eight parents and four siblings, 4% of the total sample tested) are homozygous null for exon 7 only. Two asymptomatic parents from two SMA families (representing 0.7% of the total samples, but 0.9% of the parents tested) are homozygous null for both exons 7 and 8. Table 1 shows the results of screening 280 asymptomatic family members of SMA patients for the presence or absence of SMN T exons 7 and 8. The sample consisted of unaffected parents and siblings. All SMA families meet diagnostic criteria established by the 'International SMA Consortium' (22) . Twelve individuals were lacking both copies (homozygous null) of SMN T exon 7 only, and two individuals were homozygous null for both SMN T exons 7 and 8. Figure 1 shows three families in which unaffected family members are apparently missing both copies of the SMN T exon 7 band. In each of these families, the SMN T exon 7 band (lower closed arrow in the upper panel) is present in one parent (open symbol), missing in the affected proband (black symbol), and missing in one asymptomatic parent and one sibling (stippled symbol). Analysis of SMN T exon 8 in these families (see upper closed arrow in the lower panel) shows that only the affected proband is homozygously missing this exon. Closer inspection of the exon 7 profiles suggests the presence of two additional bands labeled 'a' and 'b' in the asymptomatic family members with apparent deletions. Band 'a' was separated from the overlapping SMN C exon 7 band on a longer gel and its DNA sequence was determined. Band 'a' was shown to contain a 'C' nucleotide at base pair position 873 denoting the SMN T locus (data not shown). The same band contains an A to G polymorphism in the intronic sequence 96 bp 5′ to the start of exon 7. This polymorphism alters the band migration such that the SSCP pattern mimics the pattern of a homozygous null for SMN T exon 7. The band 'b' sequence is the exact complement of band 'a', verifying that bands 'a' and 'b' are the two complementary strands of the same locus. Haplotype analysis of families 2532 and 7322 using CA-repeat microsatellite markers flanking the SMN gene locus (13) are shown in Figure 2 . The combination of SMN and microsatellite genotypes shows that affected probands inherit two SMN T null alleles while the healthy siblings inherit a null allele from one parent along with a polymorphic variant of SMN T exon 7 from the other parent. Thus, the asymptomatic siblings appear to be homozygous nulls by SSCP analysis, but actually inherit a normal, presumably functional copy of SMN T exon 7. Analysis of the remaining six asymptomatic family members (five parents and one sibling) with apparent exon 7 deletions likewise revealed polymorphic variants of the SMN T specific exon. Figure 3 shows the SSCP results from a family with an asymptomatic parent who is a homozygous null for SMN T exons 7 and 8. In this family the proband is affected with SMA type II. His mother is clinically asymptomatic witnessed by a thorough neurological examination and by a demanding professional career and active life-style. The maternal uncle is affected with type III SMA. The diagnosis for both affected individuals was confirmed by muscle biopsy and EMG. SSCP analysis shows that the affected uncle and son, as well as the asymptomatic mother, are missing both exons 7 and 8 of SMN T . Haplotype analysis with markers spanning the SMA region (13) indicate that the mother and her affected brother have inherited identical disease alleles from their parents (Fig. 4) . Barring an undetected de novo mutation in the affected brother, the affected status in these two siblings appears to be determined by background genetic or environmental factors. We investigated further by obtaining a muscle biopsy and EMG from the mother. Her muscle biopsy revealed a mild neurogenic atrophy of muscle fibers and her EMG showed evidence of fasciculation. In view of the full DNA marker and phenotypic data, it is clear that this family is a case of autosomal recessive inheritance where the mother is homozygous for the disease allele. It is interesting that in the absence of SMN data, this family would be confused with a chromosome 5 unlinked family, or an autosomal dominant SMA family.
RESULTS
Figures 5 and 6 describe a second family with an asymptomatic parent who is homozygous null for both SMN T exons 7 and 8. The asymptomatic father as well as two type III affected offsprings are missing exons 7 and 8 (Fig. 5) . The mother and two unaffected siblings are hemizygous for exons 7 and 8. Microsatellite haplotype analysis of this family (Fig. 6) shows that the two affected children actually inherit different disease alleles from their father. The most likely explanation for this observation is that both paternal alleles have relatively 'mild' deletions (or rearrangements) which compensate one another to provide a minimum threshold of SMN T protein activity. Alternatively, some presumably unlinked gene product, expressed in the father but not transmitted to his two affected offspring, compensates the homozygous SMN T deletions. We also obtained further neurodiagnostic studies from the father. The results show a mild axonal sensorimotor peripheral neuropathy in EMG and no abnormalities in fiber size or distribution in muscle biopsy (see Materials and Methods). These results show no evidence of motor neuron disorder. Therefore the father is asymptomatic for SMA by both clinical examination and electrophysiological and histopathological studies.
DISCUSSION
We describe two individuals with homozygous null deletion of telomeric SMN exons 7 and 8 who demonstrate no clinical symptoms of SMA. In one case, an SMA type III brother and his asymptomatic sister appear to inherit identical 'disease alleles', one of which is transmitted to the son with type II SMA. EMG and muscle biopsy show that the sister has mild neurogenic pathology consistent with a mild, 'asymptomatic' manifestation of SMA. Barring an undetected de novo mutation in the affected brother, this result suggests that other factors, genetic or environmental, may compensate for the loss of SMN T function. If genetic in nature, such factors presumably map outside the immediate disease gene region. The second individual is an asymptomatic father of SMA children who is homozygous null for SMN T exons 7 and 8. In contrast to the aforementioned asymptomatic carrier, this individual shows no sign of SMA either by clinical examination or by neurodiagnostic studies. Interestingly, either of his homologues, in combination with the maternal SMA homologue, leads to typical SMA in the offspring.
The data from both families are consistent, therefore, with the notion that deletion of SMN T exons 7 and 8 per se is not sufficient to account for the clinical symptoms typical of SMA. Several explanations could account for this observation. First, homozygous deletion of SMN T exons 7 and 8 is normally sufficient to produce SMA symptoms, but in rare cases, compensating factors protect against the manifestation of disease symptoms. Such factors might include a quantitative or qualitative alteration of the SMN C gene; a third SMN homologue; or an unlinked, background gene product. Second, the majority of SMA homologues are likely to be homozygous null for the entire SMN T coding sequence. In rare circumstances, deletion, gene conversion or unequal recombination may produce a partial SMN T gene which is truncated, converted or recombined with the 3′ portion of SMN C . This variant SMN protein may retain sufficient function to allay the onset of symptoms. It is noteworthy that no groups have successfully identified deletion breakpoints within the SMN T gene. Third, the majority of SMA mutations may include critical DNA sequence (which is not Figure 1 . The proband and his maternal uncle are diagnosed with SMA type II and type III, respectively, based upon muscle biopsy and EMG. The mother is clinically asymptomatic. The two affected individuals, as well as the asymptomatic mother of the proband, are lacking both copies of SMN T exons 7 and 8. deleted in these two asymptomatic parents) in addition to the SMN T and NAIP gene sequences. This interpretation implicates yet another gene product in the development of SMA.
The identification of polymorphic variants of SMN T exon 7 that masquerade as null alleles provides a cautionary note to the interpretation of prenatal and diagnostic tests. In those cases where only SMN T exon 7 is missing, it will be important to distinguish null alleles from polymorphic alleles. This is particularly important when the assay is used in prenatal diagnosis where false positives may lead to unnecessary termination of pregnancy. Direct sequence analysis of the SSCP bands may be necessary for verification of the exon subforms, particularly when novel bands are present. Alternatively, a PCR-enzyme digestion method can be used to confirm the SSCP results (21).
Two research groups have recently reported deletion of the SMN T gene in unaffected family members of SMA patients Haplotype analysis was performed as described in Figure 2 . The asymptomatic father (I-2) and his two affected offspring are lacking both copies of SMN T exons 7 and 8. The asymptomatic mother and the two unaffected offspring are heterozygous for the loss of SMN T exons 7 and 8. The affected son (II-3) inherits the paternal homologue (2 7 3 --1) while the affected daughter (II-4) inherits the other paternal homologue (1 1 9 --2). (18, 19) . In the study of Cobben et al. (18) , four unaffected siblings from two SMA families were found to harbor homozygous deletions of SMN T exons 7 and 8. In the study of Hahnen et al. (19) , one mother and six unaffected siblings from four SMA families showed homozygous deletions of exons 7 and 8 of the SMN T gene. All of these unaffected siblings display the same microsatellite haplotypes as their respective probands. Our data are consistent with these recent findings and extend the observations by describing one homozygous null SMN T (exons 7 and 8) individual with a subclinical SMA phenotype, and another 'null' individual whose neurodiagnostic studies showed no pattern of motor neuron disease. Our data likewise indicate that misinterpretation of an SMN T exon 7 'null' genotype is possible due to the existence of polymorphic variation in this region. Cobben et al. used a PCR-enzyme digestion method to screen for SMN T deletions (21); therefore, misinterpretation due to polymorphic variation is unlikely. The nonradioactive SSCP method used in the study of Hahnen et al., however, would be susceptible to the type misinterpretation we have described due to polymorphic variation. Therefore, careful examination of SSCP bands and direct sequencing may be needed to verify that these individuals are actually homozygous null for exon 7.
Our data indicate that about 1% of SMA parents harbor two disease alleles and that some of these asymptomatic parents are likely to have a mild neurogenic pathology similar to that seen in SMA patients. The occurrence of homozygous disease alleles among asymptomatic parents should alert medical professionals involved in the genetic counseling of SMA families. The small fraction of SMA families that appear to be unlinked to chromosome 5q13 DNA markers will likely be enriched for SMA parents with this genotype. Family 1116 (Fig. 6) illustrates this occurrence. This family as well as five others in our collection initially appeared to be unlinked to chromosome 5q13 DNA markers. With one exception, we have found SMN T deletions in all these families (data not shown). The exception proved to be a case of misdiagnosis.
MATERIALS AND METHODS

Family ascertainment and diagnosis
SMA families were obtained through Muscular Dystrophy Association clinics in the United States and through an international group of collaborators. All cases of SMA were diagnosed according to consensus criteria established by an international SMA consortium (22) . Family 6376 was referred by a local genetic counselor. The 3 year old proband was diagnosed with SMA type II at 18 months old. The maternal uncle is 32 years old and diagnosed with SMA type III (Kugelberg-Welander disease) at 14 years of age. The mother is 33 years old and clinically asymptomatic. She lives an active life-style including a demanding professional occupation and regular aerobic exercise. Her muscle biopsy shows mild neurogenic atrophy and the EMG shows presence of fasciculation consistent with SMA. Family 1116 includes two affected children diagnosed at ages 13 and 11 with SMA type III. All cases of SMA were confirmed by EMG and muscle biopsy. The asymptomatic father had clubfeet at birth but exhibits no sign of motor disability at age 60. His electrophysiological studies show mild motor conduction slowing and reduced sensory amplitude consistent with axonal sensory-motor peripheral neuropathy. His EMG shows no active denervation. His muscle biopsy shows normal fiber size (no atrophy or hypertrophy) and no fiber type grouping. These studies indicate no sign of motor neuron disorder.
Haplotype analysis
Microsatellite markers D5S1411, D5S1413, D5S1414 and D5S1408 were used to genotype SMA families 6376 and 1116 according to a previously published procedure (13) .
SSCP assays
PCR primers for exon 7 (R111 and 540C770) and exon 8 (541C960 and 541C1120) were derived from previously published sequences (15) . One hundred ng of genomic DNA was added to 25 µl of reaction mix containing 25 µM of primers, 2.5 mM MgCl 2 , 1 U of Taq polymerase (Perkin-Elmer), and 2.5 µCi of [α-32 P]dCTP (New England Nuclear). The PCR reaction includes an initial 11 cycles of 30 s at 90_C, 30 s at 65-55_C with 1_C decrement per cycle, and 30 s at 72_C. This was followed by an additional 24 cycles of 30 s at 90_C, 55_C and 72_C each and a final step of 5 min at 72_C. Four µl of the PCR product were added to an equal volume of denaturing dye containing 96% formamide, 20 mM EDTA, 0.05% bromophenol blue and 0.05% xylene cyanol. The mixtures were denatured at 95_C for 10 min then chilled on ice and loaded on to a 0.5×MDE gel (MDE TM , AT Biochem, PA). The gel was run at 4 W for 18-20 h in 4_C followed by autoradiography.
DNA sequence analysis
To verify the exon subforms of the SSCP bands, we excised the bands directly from the SSCP gel. The single-stranded DNA retained in the gel was eluted by soaking in 20 µl of TE buffer (10 mM Tris and 1 mM EDTA) for 2 h in room temperature. Five µl of the eluent was used for PCR amplification. The purified PCR products were then DNA sequenced using the original oligonucleotide primers and a DyeDeoxy terminator cycle sequencing kit (Applied Biosystem).
